Literature DB >> 18249038

Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Arvind Chhabra1, Nitya G Chakraborty, Bijay Mukherji.   

Abstract

Dendritic cells (DC) present antigenic epitopes to and activate T cells. They also polarize the ensuing T cell response to Th1 or Th2 type response, depending on their cytokine production profile. For example, IL-12 producing DC generate Th1 type T cell response whereas IL-10 producing DC is usually tolerogenic. Different strategies--such as the use of cytokines and anti-cytokine antibodies, dominant negative forms of protein, anti-sense RNA etc.--have been employed to influence the cytokine synthetic profile of DC as well as to make DC more immunogenic. Utilizing GFP expressing recombinant adenoviruses in association with lipid-mediated transfection of siRNA, we have silenced the endogenous IL-10 gene in DC. We show that IL-10 gene silenced DC produces more IL-12 and also generates a better cytolytic T cell response against the human melanoma associated epitope, MART-1(27-35), in vitro. We also show that the GFP expressing adenoviral vector can be used to optimize the parameters for siRNA delivery in primary cells and show that RNA interference methodology can efficiently knock down virus encoded genes transcribed at very high multiplicity of infection in DC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18249038      PMCID: PMC2352151          DOI: 10.1016/j.clim.2007.11.011

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  35 in total

1.  RNA interference is mediated by 21- and 22-nucleotide RNAs.

Authors:  S M Elbashir; W Lendeckel; T Tuschl
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

Review 2.  Dendritic cell subsets and the regulation of Th1/Th2 responses.

Authors:  R Maldonado-López; M Moser
Journal:  Semin Immunol       Date:  2001-10       Impact factor: 11.130

3.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.

Authors:  Guangchao Sui; Christina Soohoo; El Bachir Affar; Frédérique Gay; Yujiang Shi; William C Forrester; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 4.  Dendritic cell regulation of TH1-TH2 development.

Authors:  M Moser; K M Murphy
Journal:  Nat Immunol       Date:  2000-09       Impact factor: 25.606

5.  Small interfering RNA-mediated gene silencing in T lymphocytes.

Authors:  Michael T McManus; Brian B Haines; Christopher P Dillon; Charles E Whitehurst; Luk van Parijs; Jianzhu Chen; Phillip A Sharp
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

7.  Getting peptide vaccines to work: just a matter of quality control?

Authors:  Esteban Celis
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 8.  Dendritic cell based tumor vaccines.

Authors:  M Nouri-Shirazi; J Banchereau; J Fay; K Palucka
Journal:  Immunol Lett       Date:  2000-09-15       Impact factor: 3.685

9.  Regulatory activity of autocrine IL-10 on dendritic cell functions.

Authors:  S Corinti; C Albanesi; A la Sala; S Pastore; G Girolomoni
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

10.  A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA.

Authors:  Gustavo Tiscornia; Oded Singer; Masahito Ikawa; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more
  14 in total

Review 1.  RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy.

Authors:  Fang Cheng; Song He
Journal:  Mol Biol Rep       Date:  2009-09-12       Impact factor: 2.316

2.  Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.

Authors:  Valentina Di Caro; Antonella D'Anneo; Brett Phillips; Carl Engman; Jo Harnaha; Massimo Trucco; Nick Giannoukakis
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 3.  Immune evasion pathways and the design of dendritic cell-based cancer vaccines.

Authors:  Brent A Hanks
Journal:  Discov Med       Date:  2016-02       Impact factor: 2.970

Review 4.  Engineering better immunotherapies via RNA interference.

Authors:  Mouldy Sioud
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Dendritic Cells Loaded with Tumor Antigens and a Dual Immunostimulatory and Anti-Interleukin 10-Specific Small Interference RNA Prime T Lymphocytes against Leukemic Cells.

Authors:  Per O Iversen; Elvira Semaeva; Dag R Sorensen; Helge Wiig; Mouldy Sioud
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

6.  The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.

Authors:  Pallab Pradhan; Hong Qin; Jardin A Leleux; Dongho Gwak; Ippei Sakamaki; Larry W Kwak; Krishnendu Roy
Journal:  Biomaterials       Date:  2014-04-08       Impact factor: 12.479

7.  CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.

Authors:  Arvind Chhabra; Lili Yang; Pin Wang; Begoña Comin-Anduix; Raja Das; Nitya G Chakraborty; Swagatam Ray; Shikhar Mehrotra; Haiguang Yang; Cinnamon L Hardee; Roger Hollis; David I Dorsky; Richard Koya; Donald B Kohn; Antoni Ribas; James S Economou; David Baltimore; Bijay Mukherji
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

8.  Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.

Authors:  Arvind Chhabra; Bijay Mukherji
Journal:  J Immunol       Date:  2013-08-09       Impact factor: 5.422

Review 9.  Interleukin-10: new perspectives on an old cytokine.

Authors:  David M Mosser; Xia Zhang
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

10.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.